<DOC>
	<DOCNO>NCT00498992</DOCNO>
	<brief_summary>RATIONALE : Regenecare® wound gel may help relieve pain itch patient develop acne-like rash undergo treatment cetuximab another epidermal growth factor receptor inhibitor cancer . PURPOSE : This clinical trial study well Regenecare® wound gel work treat rash patient receive cetuximab another epidermal growth factor receptor inhibitor therapy cancer .</brief_summary>
	<brief_title>Regenecare® Wound Gel Treating Rash Patients Receiving Cetuximab Other Epidermal Growth Factor Receptor Inhibitor Therapy Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine efficacy Regenecare® wound gel alleviate pain itch patient develop acneiform rash undergo treatment cetuximab EGFR inhibitor therapy cancer . Secondary - Determine efficacy drug reduce severity rash patient . - Determine efficacy drug reduce redness appearance rash patient . - Determine tolerability drug patient . OUTLINE : This prospective study . - Observation : Patients undergo evaluation full-face photography prior development skin rash ( baseline ) . While undergo concurrent cancer therapy , patient self-monitor appearance acneiform rash . Upon initial onset rash , patient proceed treatment . - Treatment : Patients apply topical Regenecare® wound gel face ≥ 4 time daily . Treatment continue 4 week absence unacceptable toxicity . Patients evaluate weekly facial examination , full-face photography , patient satisfaction questionnaire .</detailed_description>
	<mesh_term>Lidocaine</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Vitamin E</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis cancer Starting treatment cetuximab EGFR inhibitor ( e.g. , erlotinib hydrochloride ) another clinical trial PATIENT CHARACTERISTICS : Not pregnant nursing No known history hypersensitivity aminetype local anesthetic component MPM Regenecare® wind gel No concurrent , serious skin disorder ( i.e. , scleroderma psoriasis ) would interfere assessment EGFR inhibitorinduced rash PRIOR CONCURRENT THERAPY : See Disease Characteristics No concurrent topical facial cream lotion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>dermatologic complication</keyword>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>